Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer

No open prediction endpoints

Endpoints are classified and published by ProgramSignal analysts.

Key Facts

Primary Endpoints (CT.gov)

Secondary Endpoints

Eligibility Criteria

Inclusion Criteria: * Written informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization for release of personal health information prior to registration * Males age ≥ 18 years with progressive metastatic, castration-resistant prostate cancer, previous adenocarcinoma histology confirmation required * Ability to understand a written informed consent document, as determined by the study physician or designee * Surgical castration or continuous medical castration ≥ 8 weeks prior to screening; serum testosterone \< 50 ng/dL * Have progressed on prior abiraterone treatment by Prostate Cancer Working Group 3 prostate specific antigen (PSA) criteria * PSA must rise on two measurements at least 1 week apart in order to be eligible. Refer to PCWG3 for clarification. * Most Recent absolute PSA must be \> 2.0 ng/mL * Patient meets definition of poor responder to abiraterone by one of the following: * Abiraterone started in hormone-sensitive prostate ca…

✦ Analyst Commentary

Expert commentary on why this trial matters and what to watch for.

Source